Clinical response of psoriasis to subcutaneous methotrexate correlates with inhibition of cutaneous T helper 1 and 17 inflammatory pathways

doi:10.1111/bjd.18001

Clinical Trial

. 2019 Oct;181(4):859-862.

doi: 10.1111/bjd.18001. Epub 2019 Jul 1.

Clinical response of psoriasis to subcutaneous methotrexate correlates with inhibition of cutaneous T helper 1 and 17 inflammatory pathways

K Reich^{1

2}, J L K Reich³, T M Falk⁴, N Blödorn-Schlicht⁴, U Mrowietz⁵, R von Kiedrowski⁶, C Pfeiffer⁷, J Niesmann⁸, Y Frambach⁹, R B Warren¹⁰

Affiliations

¹ Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Germany.
² Skinflammation Center, Hamburg, Germany, Dermatologikum Berlin, Berlin, Germany.
³ School of Medicine, Imperial College London, U.K.
⁴ Dermatologikum Hamburg, Hamburg, Germany.
⁵ Psoriasis-Centre, Department of Dermatology, University Medical Centre Schleswig-Holstein, Kiel, Germany.
⁶ Company for Medical Study & Service, Selters, Germany.
⁷ Department of Dermatology and Allergology, University of Ulm, Germany.
⁸ Hautzentrum im Jahrhundert Haus - Centre for Clinical Trials, Bochum, Germany.
⁹ Hautarztpraxis Lübeck, Lübeck, Germany.
¹⁰ Dermatological Sciences, University of Manchester, Manchester, U.K.

PMID: 30972731
DOI: 10.1111/bjd.18001

Clinical Trial

Clinical response of psoriasis to subcutaneous methotrexate correlates with inhibition of cutaneous T helper 1 and 17 inflammatory pathways

K Reich et al. Br J Dermatol. 2019 Oct.

. 2019 Oct;181(4):859-862.

doi: 10.1111/bjd.18001. Epub 2019 Jul 1.

Authors

K Reich^{1

2}, J L K Reich³, T M Falk⁴, N Blödorn-Schlicht⁴, U Mrowietz⁵, R von Kiedrowski⁶, C Pfeiffer⁷, J Niesmann⁸, Y Frambach⁹, R B Warren¹⁰

Affiliations

¹ Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Germany.
² Skinflammation Center, Hamburg, Germany, Dermatologikum Berlin, Berlin, Germany.
³ School of Medicine, Imperial College London, U.K.
⁴ Dermatologikum Hamburg, Hamburg, Germany.
⁵ Psoriasis-Centre, Department of Dermatology, University Medical Centre Schleswig-Holstein, Kiel, Germany.
⁶ Company for Medical Study & Service, Selters, Germany.
⁷ Department of Dermatology and Allergology, University of Ulm, Germany.
⁸ Hautzentrum im Jahrhundert Haus - Centre for Clinical Trials, Bochum, Germany.
⁹ Hautarztpraxis Lübeck, Lübeck, Germany.
¹⁰ Dermatological Sciences, University of Manchester, Manchester, U.K.

PMID: 30972731
DOI: 10.1111/bjd.18001

No abstract available

PubMed Disclaimer

Cited by

Skin Barrier Dysregulation in Psoriasis.
Orsmond A, Bereza-Malcolm L, Lynch T, March L, Xue M. Orsmond A, et al. Int J Mol Sci. 2021 Oct 7;22(19):10841. doi: 10.3390/ijms221910841. Int J Mol Sci. 2021. PMID: 34639182 Free PMC article. Review.
Beyond-Mild Psoriasis: A Consensus Statement on Calcipotriol and Betamethasone Dipropionate Foam for the Topical Treatment of Adult Patients.
Aschoff R, Bewley A, Dattola A, De Simone C, Lahfa M, Llamas-Velasco M, Martorell A, Pavlovic M, Sticherling M. Aschoff R, et al. Dermatol Ther (Heidelb). 2021 Oct;11(5):1791-1804. doi: 10.1007/s13555-021-00600-1. Epub 2021 Sep 12. Dermatol Ther (Heidelb). 2021. PMID: 34510404 Free PMC article.
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Guelimi R, Garcia-Doval I, Hua C, Hughes C, Naldi L, Kinberger M, Afach S, Le Cleach L. Sbidian E, et al. Cochrane Database Syst Rev. 2023 Jul 12;7(7):CD011535. doi: 10.1002/14651858.CD011535.pub6. Cochrane Database Syst Rev. 2023. PMID: 37436070 Free PMC article. Review.
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Garcia-Doval I, Doney L, Dressler C, Hua C, Hughes C, Naldi L, Afach S, Le Cleach L. Sbidian E, et al. Cochrane Database Syst Rev. 2022 May 23;5(5):CD011535. doi: 10.1002/14651858.CD011535.pub5. Cochrane Database Syst Rev. 2022. Update in: Cochrane Database Syst Rev. 2023 Jul 12;7:CD011535. doi: 10.1002/14651858.CD011535.pub6 PMID: 35603936 Free PMC article. Updated. Review.
IL-17 Pathway Members as Potential Biomarkers of Effective Systemic Treatment and Cardiovascular Disease in Patients with Moderate-to-Severe Psoriasis.
Wang X, Kaiser H, Kvist-Hansen A, McCauley BD, Skov L, Hansen PR, Becker C. Wang X, et al. Int J Mol Sci. 2022 Jan 5;23(1):555. doi: 10.3390/ijms23010555. Int J Mol Sci. 2022. PMID: 35008981 Free PMC article.

See all "Cited by" articles

References

1. Boffa MJ, Chalmers RJ. Methotrexate for psoriasis. Clin Exp Dermatol 1996; 21:399-408.
1. Barker J, Hoffmann M, Wozel G et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol 2011; 165:1109-17.
1. Reich K, Langley RG, Papp KA et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med 2011; 365:1586-96.
1. Warren RB, Mrowietz U, von Kiedrowski R et al. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 389:528-53.
1. Stamp LK, Barclay ML, O'Donnell JL et al. Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritis. J Rheumatol 2011; 38:2540-7.

Publication types

Actions
Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

Grants and funding

Medac Germany/International

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Boffa MJ, Chalmers RJ. Methotrexate for psoriasis. Clin Exp Dermatol 1996; 21:399-408.

[2] Boffa MJ, Chalmers RJ. Methotrexate for psoriasis. Clin Exp Dermatol 1996; 21:399-408.

[3] Barker J, Hoffmann M, Wozel G et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol 2011; 165:1109-17.

[4] Barker J, Hoffmann M, Wozel G et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol 2011; 165:1109-17.

[5] Reich K, Langley RG, Papp KA et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med 2011; 365:1586-96.

[6] Reich K, Langley RG, Papp KA et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med 2011; 365:1586-96.

[7] Warren RB, Mrowietz U, von Kiedrowski R et al. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 389:528-53.

[8] Warren RB, Mrowietz U, von Kiedrowski R et al. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 389:528-53.

[9] Stamp LK, Barclay ML, O'Donnell JL et al. Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritis. J Rheumatol 2011; 38:2540-7.

[10] Stamp LK, Barclay ML, O'Donnell JL et al. Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritis. J Rheumatol 2011; 38:2540-7.

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Clinical response of psoriasis to subcutaneous methotrexate correlates with inhibition of cutaneous T helper 1 and 17 inflammatory pathways

Affiliations

Clinical response of psoriasis to subcutaneous methotrexate correlates with inhibition of cutaneous T helper 1 and 17 inflammatory pathways

Authors

Affiliations

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Medical